GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Welcure Drugs & Pharmaceuticals Ltd (BOM:524661) » Definitions » Debt-to-EBITDA

Welcure Drugs & Pharmaceuticals (BOM:524661) Debt-to-EBITDA : 0.00 (As of Dec. 2024)


View and export this data going back to 2000. Start your Free Trial

What is Welcure Drugs & Pharmaceuticals Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Welcure Drugs & Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was ₹0.0 Mil. Welcure Drugs & Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was ₹0.0 Mil. Welcure Drugs & Pharmaceuticals's annualized EBITDA for the quarter that ended in Dec. 2024 was ₹36.7 Mil. Welcure Drugs & Pharmaceuticals's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2024 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Welcure Drugs & Pharmaceuticals's Debt-to-EBITDA or its related term are showing as below:

BOM:524661's Debt-to-EBITDA is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.595
* Ranked among companies with meaningful Debt-to-EBITDA only.

Welcure Drugs & Pharmaceuticals Debt-to-EBITDA Historical Data

The historical data trend for Welcure Drugs & Pharmaceuticals's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Welcure Drugs & Pharmaceuticals Debt-to-EBITDA Chart

Welcure Drugs & Pharmaceuticals Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Welcure Drugs & Pharmaceuticals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Welcure Drugs & Pharmaceuticals's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Welcure Drugs & Pharmaceuticals's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Welcure Drugs & Pharmaceuticals's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Welcure Drugs & Pharmaceuticals's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Welcure Drugs & Pharmaceuticals's Debt-to-EBITDA falls into.



Welcure Drugs & Pharmaceuticals Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Welcure Drugs & Pharmaceuticals's Debt-to-EBITDA for the fiscal year that ended in Mar. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / -1.388
=0.00

Welcure Drugs & Pharmaceuticals's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2024) EBITDA data.


Welcure Drugs & Pharmaceuticals  (BOM:524661) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Welcure Drugs & Pharmaceuticals Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Welcure Drugs & Pharmaceuticals's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Welcure Drugs & Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
Laxmi Nagar, Plot No. 55, Office No. 104, First Floor, Vijay Block, Delhi East, Delhi, Delhi, IND, 110092
Welcure Drugs & Pharmaceuticals Ltd is a pharmaceutical company. The company is principally engaged in the manufacturing of pharmaceutical products. The company has one operating segment: Providing services for procurements of order.

Welcure Drugs & Pharmaceuticals Headlines

No Headlines